



CONTACTS: Ellen Semple  
BioAdvance  
(215) 966-6207  
[esemple@bioadvance.com](mailto:esemple@bioadvance.com)

Barbara Lindheim  
GendeLLindheim BioCom Partners  
(212) 918-4650

**For Release November 18, 7:00AM ET**

## **BIOADVANCE NAMES DR. MICHAEL PELLINI AS FIRST ENTREPRENEUR-IN-RESIDENCE**

*--Former Biotech Physician/CEO Brings Expertise in Managing Business Innovation to Greater Philadelphia Bioinformatics Alliance--*

**Philadelphia – November 18, 2004** – BioAdvance, the Biotechnology Greenhouse of Southeastern Pennsylvania, today announced the appointment of Michael Pellini, M.D., MBA, as the organization’s first “entrepreneur-in-residence.” As a founding member of the Greater Philadelphia Bioinformatics Alliance (GPBA), BioAdvance created this new role so that Dr. Pellini may assist in propelling the GPBA, a regional coalition comprised of academia, research institutions, and private sector entities in an effort to ultimately provide new solutions to major medical and life sciences challenges. With a unique background and expertise spanning medicine, business management and business development, Dr. Pellini will also assist related emerging life sciences companies in the BioAdvance portfolio with business and strategic counsel.

“As a former biotech CEO and physician with experience in investment banking, Mike brings us a wealth of experience directly relevant to both the GPBA and BioAdvance,” said Gary Kurtzman, M.D., managing director and chief operating officer of BioAdvance. “His strong capabilities in building successful relationships between commercial and academic researchers and his proven success in building a unique entrepreneurial venture in translational medicine will provide tremendous value.”

Dr. Pellini comes to this position after serving five years as CEO of the Boston-based biotech firm Genomics Collaborative, Inc. (GCI), recently acquired by California-based SeraCare Life Sciences, Inc. GCI, co-founded by Malvern, PA-based Michael Wall, who also served as the founder of Centocor, developed unique expertise in applying the science of genomics to complex drug and diagnostic discovery decisions. GCI's scientists and their innovative technology offered a highly efficient platform to discover and validate genomics-based drug and diagnostic targets. Its position in the market was supported through partnerships with more than 30 pharmaceutical and biotechnology companies.

In joining BioAdvance, Dr. Pellini returns to his Philadelphia roots, having received his medical degree from the Jefferson Medical College of Thomas Jefferson University and his MBA from Drexel University. “I was eager to return to Philadelphia, an area rich in scientific and medical resources just now beginning to be fully tapped,” said Dr. Pellini. “I look forward to the challenges and rewards of working with many of the region’s talented researchers and entrepreneurs. These BioAdvance programs, made possible by the forward thinking of the Commonwealth of Pennsylvania, have the potential to greatly impact both our local economy and human health.”

Prior to his positions in the biotech industry, Dr. Pellini trained as a primary care physician in the Thomas Jefferson University Health System. Before attending medical school, he worked in the investment banking industry in both Philadelphia and Sydney, Australia. Dr. Pellini serves on the Board of Directors for Genomics Collaborative, Inc. and Malvern Pharmaceuticals, Inc., the Board of Trustees for the Coriell Institute of Medical Research, the Editorial Board for Biotechnology Healthcare, the Executive Committee for Jefferson Medical College, and the Biotech Council of Boston College.

### **About BioAdvance**

As a critical part of a \$2 billion initiative by the Commonwealth of Pennsylvania to simultaneously support life sciences technologies and stimulate the economy, BioAdvance received \$33.8 million from the State's share of the tobacco settlement monies to accelerate the creation of life sciences jobs and businesses in Southeastern Pennsylvania. BioAdvance will accomplish this goal through its key funding program, the Greenhouse Fund, and other initiatives to link entrepreneurs to the region's wealth of resources. For information about BioAdvance, please visit [www.bioadvance.com](http://www.bioadvance.com).

### **About the Greater Philadelphia Bioinformatics Alliance**

The Greater Philadelphia Bioinformatics Alliance (GPBA) is a consortium of regional research and academic organizations dedicated to advancing the field of bioinformatics—the integration of biology and advanced computation sciences that is revolutionizing life science research and holds the promise for significantly improved healthcare. By linking together the region's broad knowledge base of talented bioinformatics workers in academia, research institutions and the private sector, The Greater Philadelphia Bioinformatics Alliance is working to provide new solutions to major medical, life sciences and environmental challenges. For more information, visit the GPBA website at [www.gpba-bio.com](http://www.gpba-bio.com).